Pharmacokinetics of a valpromide isomer, valnoctamide, in healthy subjects

Eur J Clin Pharmacol. 1990;38(3):289-91. doi: 10.1007/BF00315032.


The pharmacokinetics of a single 400 mg oral dose of valnoctamide (VCD) has been investigated in seven healthy, adult, male volunteers. VCD was not biotransformed rapidly to its corresponding acid valnoctic acid (VCA), unlike its isomer valpromide (VPD). It had a mean residence time of 13.2 h and a terminal half-life of 9.3 h. Throughout the study, only low plasma levels of VCA could be detected. Thus, unlike VPD, which is a pro-drug of the corresponding acid, (valproic acid, VPA). VCD appears to act as a drug in its own right, and it does not undergo similar hydrolysis. The pharmacokinetic difference may account for the different pharmacological activities of the two isomers.

MeSH terms

  • Adult
  • Amides / pharmacokinetics*
  • Half-Life
  • Humans
  • Isomerism
  • Male
  • Valproic Acid / analogs & derivatives
  • Valproic Acid / pharmacokinetics*


  • Amides
  • valnoctamide
  • Valproic Acid
  • dipropylacetamide